IBM Watson Health signed a five-year deal with Israeli startup MedyMatch to integrate the latter’s artificial intelligence-based technology to better detect bleeding in the brain due to head trauma or stroke. (See also, IBM Watson Partners With FDA to Secure Health Data.)
IBM Watson Health uses artificial intelligence (AI) to assist doctors with improved disease diagnosis and cures. MedyMatch is building cognitive applications that are aimed at quicker and accurate assessment of patients prone to have head trauma or stroke. MedyMatch’s technology combines advanced in-depth learning, cognitive analytics, key data-points of the patient, and clinical inputs to help spot the presence of intracranial (within the skull) bleeding.
Benchmark data and examples are fed into the computer to set a baseline, followed by uploading multiple images that assist the system to efficiently and accurately identify possible brain bleed. MedyMatch claims to have secured billions of relevant images from millions of cases via collaborations with hospitals in Israel and the U.S.
The long-term agreement will initially involve IBM Watson Health utilizing its sales channels to distribute MedyMatch's brain bleed detection application at a global level. The next phase will have the two companies jointly developing interoperability between MedyMatch's application and IBM Watson Health Imaging solutions.
The Israeli startup is performing a clinical assessment of its intracranial bleed assessment application, and is working towards securing a pre-market approval for its application from the U.S. Food And Drug Administration (FDA).
Though exact financials of the deal are not disclosed, MedyMatch is expected to benefit with several millions of dollars in annual recurring licensing fees from IBM during the five-year deal. The target market is big, as stroke ranks fourth among the leading causes of deaths in America, with 4% of adults are prone to the preventable disease. It is estimated that America will have 3.4 million stroke-affected individuals by 2030, which will cost $240 billion each year to the U.S. healthcare. (See also, IBM's Watson Meets Salesforce's Einstein in New Partnership.)